Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Treasury Shares (2022 - 2025)

Gain Therapeutics has reported Treasury Shares over the past 4 years, most recently at $24568.0 for Q3 2025.

  • Quarterly results put Treasury Shares at $24568.0 for Q3 2025, down 76.08% from a year ago — trailing twelve months through Sep 2025 was $24568.0 (down 76.08% YoY), and the annual figure for FY2024 was $102702.0, down 79.2%.
  • Treasury Shares for Q3 2025 was $24568.0 at Gain Therapeutics, down from $28833.0 in the prior quarter.
  • Over the last five years, Treasury Shares for GANX hit a ceiling of $598150.0 in Q2 2023 and a floor of $24568.0 in Q3 2025.
  • Median Treasury Shares over the past 4 years was $212089.5 (2023), compared with a mean of $253685.8.
  • Biggest five-year swings in Treasury Shares: surged 62.94% in 2023 and later plummeted 79.71% in 2024.
  • Gain Therapeutics' Treasury Shares stood at $303050.0 in 2022, then skyrocketed by 62.94% to $493799.0 in 2023, then crashed by 79.2% to $102702.0 in 2024, then tumbled by 76.08% to $24568.0 in 2025.
  • The last three reported values for Treasury Shares were $24568.0 (Q3 2025), $28833.0 (Q2 2025), and $91149.0 (Q1 2025) per Business Quant data.